Department of Cardiology and Internal Medicine, Collegium Medicum, Nicolaus Copernicus University, 85-094 Bydgoszcz, Poland.
Division of Cardiovascular Medicine, University of California San Diego, La Jolla, CA 92037, USA.
Int J Mol Sci. 2023 Mar 28;24(7):6382. doi: 10.3390/ijms24076382.
Cardiometabolic diseases (CMDs), including cardiovascular disease (CVD), metabolic syndrome (MetS), and type 2 diabetes (T2D), are associated with increased morbidity and mortality. The growing prevalence of CVD is mostly attributed to the aging population and common occurrence of risk factors, such as high systolic blood pressure, elevated plasma glucose, and increased body mass index, which led to a global epidemic of obesity, MetS, and T2D. Oxidant-antioxidant balance disorders largely contribute to the pathogenesis and outcomes of CMDs, such as systemic essential hypertension, coronary artery disease, stroke, and MetS. Enhanced and disturbed generation of reactive oxygen species in excess adipose tissue during obesity may lead to increased oxidative stress. Understanding the interplay between adiposity, oxidative stress, and cardiometabolic risks can have translational impacts, leading to the identification of novel effective strategies for reducing the CMDs burden. The present review article is based on extant results from basic and clinical studies and specifically addresses the various aspects associated with oxidant-antioxidant balance disorders in the course of CMDs in subjects with excess adipose tissue accumulation. We aim at giving a comprehensive overview of existing knowledge, knowledge gaps, and future perspectives for further basic and clinical research. We provide insights into both the mechanisms and clinical implications of effects related to the interplay between adiposity and oxidative stress for treating and preventing CMDs. Future basic research and clinical trials are needed to further examine the mechanisms of adiposity-enhanced oxidative stress in CMDs and the efficacy of antioxidant therapies for reducing risk and improving outcome of patients with CMDs.
心血管代谢疾病(CMD),包括心血管疾病(CVD)、代谢综合征(MetS)和 2 型糖尿病(T2D),与发病率和死亡率的增加有关。CVD 的患病率不断上升主要归因于人口老龄化以及常见的危险因素,如高血压、高血糖和体重指数增加,这导致了肥胖、MetS 和 T2D 的全球流行。氧化应激失衡在 CMD 的发病机制和结果中起着重要作用,如全身性原发性高血压、冠心病、中风和 MetS。肥胖期间过多脂肪组织中活性氧的增强和紊乱产生可能导致氧化应激增加。了解肥胖、氧化应激和心血管代谢风险之间的相互作用具有转化意义,有助于确定减少 CMD 负担的新的有效策略。本综述文章基于基础和临床研究的现有结果,特别针对与肥胖个体中脂肪组织堆积相关的 CMD 过程中的氧化应激失衡的各个方面。我们旨在全面概述现有的知识、知识空白和未来的研究方向,为进一步的基础和临床研究提供参考。我们深入探讨了肥胖与氧化应激之间相互作用的机制及其对治疗和预防 CMD 的临床意义。未来的基础研究和临床试验需要进一步研究 CMD 中肥胖增强的氧化应激的机制,以及抗氧化治疗在降低风险和改善 CMD 患者预后方面的疗效。